FGF-18 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is a tyrosine kinase inhibitor that directly targets FGF receptors, including FGFR3, which is involved in FGF-18 signaling. By inhibiting FGFRs, PD173074 can potentially disrupt the downstream signaling cascade activated by FGF-18, leading to the inhibition of its cellular effects. | ||||||
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $62.00 $96.00 | 36 | |
SU5402 is another tyrosine kinase inhibitor that can directly impact FGF signaling by inhibiting FGFRs. Through its action on the tyrosine kinase activity of these receptors, SU5402 can interfere with the downstream signaling events initiated by FGF-18, thus indirectly inhibiting the cellular responses mediated by FGF-18. | ||||||
BGJ398 | 872511-34-7 | sc-364430 sc-364430A sc-364430B sc-364430C | 5 mg 10 mg 50 mg 100 mg | $212.00 $247.00 $582.00 $989.00 | 4 | |
BGJ398 is a selective inhibitor of FGFRs, targeting their tyrosine kinase activity. This direct inhibition of FGFRs by BGJ398 can potentially modulate FGF-18 signaling pathways, preventing the activation of downstream cascades and consequently inhibiting the cellular responses mediated by FGF-18. | ||||||
AZD4547 | 1035270-39-3 | sc-364421 sc-364421A | 5 mg 10 mg | $198.00 $309.00 | 6 | |
AZD4547 is an FGFR tyrosine kinase inhibitor that directly interferes with FGFR signaling. By blocking the tyrosine kinase activity of FGFRs, AZD4547 can disrupt the intracellular signaling initiated by FGF-18, thereby indirectly inhibiting the cellular effects mediated by FGF-18. | ||||||
Hesperadin | 422513-13-1 | sc-490384 | 10 mg | $304.00 | ||
Hesperadin is an inhibitor of Aurora kinase B, and its indirect impact on FGF-18 involves the cell cycle. By affecting Aurora kinase B, Hesperadin influences cell division, potentially altering the cellular responsiveness to FGF-18 signaling and indirectly modulating the downstream effects of FGF-18. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a pathway implicated in FGF signaling. Through its action on PI3K, LY294002 can indirectly modulate FGF-18 responses by interfering with downstream effectors, impacting cellular processes that are under the influence of FGF-18 signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that indirectly influences FGF-18 signaling pathways. By targeting multiple kinases, including those implicated in FGF signaling, Sorafenib can disrupt the intricate network of signaling events downstream of FGF-18, resulting in indirect inhibition of the cellular effects induced by FGF-18. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
BIBF 1120 is a multi-kinase inhibitor with activity against FGFRs, and its direct impact on FGFR signaling can lead to the inhibition of FGF-18-induced cellular responses. By blocking the tyrosine kinase activity of FGFRs, BIBF 1120 can interfere with the downstream signaling pathways activated by FGF-18, indirectly inhibiting its cellular effects. | ||||||
FAK Inhibitor 14 | 4506-66-5 | sc-203950 sc-203950A | 10 mg 50 mg | $107.00 $233.00 | 86 | |
FAK Inhibitor 14, Y15, is a small molecule inhibitor of focal adhesion kinase (FAK). Its indirect impact on FGF-18 involves cellular adhesion and migration. By inhibiting FAK, Y15 can modulate cellular responses to FGF-18, potentially influencing processes such as cell migration and adhesion indirectly through the FGF-18 signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that indirectly modulates FGF-18 responses by affecting the mTOR pathway. Through its action on mTOR, Rapamycin can influence the downstream signaling cascades activated by FGF-18, impacting cellular processes that are regulated by the mTOR pathway and indirectly inhibiting the effects mediated by FGF-18. | ||||||